Exhibit 99.1


     COMPETITIVE TECHNOLOGIES ENTERS INTO $5.0 MILLION FINANCING COMMITMENT

     Proceeds to Help Fund Pain Management Medical Device Commercialization

Fairfield,  CT  (July  25,  2008)  - Competitive Technologies, Inc. (Amex: CTT),
announced  today  that  it has entered into a $5.0 million common stock purchase
agreement  with  Fusion  Capital  Fund  II,  LLC,  a Chicago-based institutional
investor. Fusion Capital has been an investor in CTT since February 2004 and has
previously  funded  the company $5.0 million. CTT may sell up to $5.0 million of
its  common  stock  to  Fusion  Capital from time to time over a 24-month period
after  the  Securities  and  Exchange  Commission  has  declared  effective  a
registration  statement  related  to  the  transaction.

In  July  2007, CTT announced that it had acquired exclusive distribution rights
to  a  pain  management  therapy  device  for  the  non-invasive  treatment  of
high-intensity  oncologic  and  neuropathic pain resistant to morphine and other
drugs.  A  portion of the proceeds from the transaction with Fusion Capital will
be  used  to  help  commercialize  and  market  this technology. CTT changed its
business  model  from  its usual royalty arrangement to one of shared profits of
manufacturing  and  distribution  for  this  breakthrough  technology, capturing
significantly  greater  market  value  for CTT than by licensing the device. The
technology  has  Medical Device CE certification for European sales, and a filed
application  for  FDA  510(k)  medical  device  authorization for US sales, that
together  may  lead  to  historically  high  levels  of  cash  flow  for  CTT.

Under  the  agreement,  CTT  has the right to sell shares of its common stock to
Fusion  Capital  from  time to time in amounts between $50,000 and $1.0 million,
depending  on  certain  conditions,  up  to  $5.0  million in the aggregate. The
purchase  price  of  the shares will be based on the prevailing market prices of
CTT's  shares  at  the  time  of  sales without any fixed discount, and CTT will
control  the  timing  and amount of any sales of shares to Fusion Capital. There
are  no  negative  covenants,  restrictions  on  future financings, penalties or
liquidated  damages  in  the  agreement.  A  more  detailed  description  of the
agreement  is set forth in CTT's current report on Form 8-K filed today with the
SEC,  which  should  be  reviewed  carefully  with  this  press  release.

"CTT  plans  to  selectively  use  this  financing  commitment  to fund targeted
marketing  and sales development of our technologies with high profit potential,
including  our  pain  management technology," said John B. Nano, CTT's Chairman,
President  and  CEO.  "The  added  financial  resources provide CTT with greater
flexibility  to  implement  our  market  focused  business commercialization. We
continue  to  market  and  build  a  technology  portfolio  that  exploits  the
opportunities  of  the  paradigm  shift resulting from record high costs of both
healthcare  and  energy. CTT is very pleased to again work with Fusion Capital."

About Fusion Capital II, LLC

Fusion  Capital  Fund  II,  LLC  is  an institutional investor based in Chicago,
Illinois  with  a  fundamental  investment approach. Fusion Capital invests in a
wide  range  of  companies  and industries emphasizing life sciences, cleantech,
energy  and  technology  companies. Its investments range from special situation
financing  to  long-term  strategic  capital.

About Competitive Technologies, Inc.

Competitive  Technologies,  established  in  1968,  is a full service technology
transfer and licensing provider focused on the technology needs of its customers
and transforming those requirements into commercially viable solutions. CTT is a
global  leader  in  identifying,  developing  and  commercializing  innovative
technologies  in  life,  electronic,  nano,  and  physical sciences developed by
universities,  companies  and inventors. CTT maximizes the value of intellectual
assets  for  the benefit of its customers, clients and shareholders. Visit CTT's
website:  www.competitivetech.net



Statements made about our future expectations are forward-looking statements and
subject to risks and uncertainties as described in our most recent Annual Report
on Form 10-K for the year ended July 31, 2007, filed with the SEC on October 29,
2007, and other filings with the SEC, and are subject to change at any time. Our
actual results could differ materially from these forward-looking statements. We
undertake  no  obligation  to  update  publicly  any  forward-looking statement.

Direct inquiries to:    Johnnie D. Johnson, IR Services, LLC
                        Tel: 860 434 2465  E-mail: jdjohnson@corpirservices.com